» Articles » PMID: 37948404

HSP70 Via HIF-1 α SUMOylation Inhibits Ferroptosis Inducing Lung Cancer Recurrence After Insufficient Radiofrequency Ablation

Overview
Journal PLoS One
Date 2023 Nov 10
PMID 37948404
Authors
Affiliations
Soon will be listed here.
Abstract

Radiofrequency ablation (RFA) is an effective and feasible therapy for lung cancer, but accelerated progression of residual non-small cell lung cancer (NSCLC) after incomplete radiofrequency ablation (RFA) has frequently been reported. A previous study reported that HSP70 and HIF-1α were highly expressed in areas with incomplete RFA. Therefore, we sought to elucidate the regulatory effect of the HIF-1α/HSP70 pathway on lung cancer recurrence after incomplete radiofrequency ablation. In this study, we found that knockdown of HSP70 can reduce sumo 1, sumo 2/3 (marker of SUMOylation) of HIF-1α and inhibit A549 cell proliferation and migration under heat stress conditions (used to simulate incomplete RFA in vitro). We observed that knockdown of HSP70 altered the expression of ferroptosis-related proteins and genes (SLC7A11 and ACSL3), and the RNA-seq results showed that knockdown of HSP70 activated the ferroptosis pathway, further confirming that HSP70 regulates ferroptosis. In summary, HSP70, via HIF-1α SUMOylation, inhibited ferroptosis, inducing lung cancer recurrence after radiofrequency ablation. The study reveals a new direction for further research on therapeutic targets to suppress lung cancer recurrence and provides a theoretical foundation for further clinical studies.

Citing Articles

Radiofrequency Ablation Versus Thoracoscopic Sublobar Resection for the Treatment of Pulmonary Ground Glass Nodules: A Retrospective Observational Study.

Zhao S, Shen L, Tong X, Jiang X, Li H, Zhao J Cardiovasc Intervent Radiol. 2025; .

PMID: 39994026 DOI: 10.1007/s00270-025-03984-1.


Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer.

Zhang J, Yao M, Xia S, Zeng F, Liu Q Cell Mol Biol Lett. 2025; 30(1):2.

PMID: 39757165 PMC: 11702238. DOI: 10.1186/s11658-024-00682-7.


Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy.

Youssef E, Zhao S, Purcell C, Olson G, El-Deiry W Front Oncol. 2024; 14:1484515.

PMID: 39697237 PMC: 11652374. DOI: 10.3389/fonc.2024.1484515.


Ferroptosis: principles and significance in health and disease.

Chen F, Kang R, Tang D, Liu J J Hematol Oncol. 2024; 17(1):41.

PMID: 38844964 PMC: 11157757. DOI: 10.1186/s13045-024-01564-3.


Enhancing the therapeutic impact of sublethal radiofrequency hyperthermia in malignant solid tumor treatment.

Liu J, Zhang G, Li X, Zheng C, Kan X Heliyon. 2024; 10(8):e29866.

PMID: 38681568 PMC: 11053292. DOI: 10.1016/j.heliyon.2024.e29866.

References
1.
Yang L, Zhang Y, Zhang Y, Fan Z . Mechanism and application of ferroptosis in colorectal cancer. Biomed Pharmacother. 2022; 158:114102. DOI: 10.1016/j.biopha.2022.114102. View

2.
Lin Z, Song J, Gao Y, Huang S, Dou R, Zhong P . Hypoxia-induced HIF-1α/lncRNA-PMAN inhibits ferroptosis by promoting the cytoplasmic translocation of ELAVL1 in peritoneal dissemination from gastric cancer. Redox Biol. 2022; 52:102312. PMC: 9043498. DOI: 10.1016/j.redox.2022.102312. View

3.
Wan J, Wu W, Huang Y, Ge W, Liu S . Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70/HIF-1α. Oncol Rep. 2016; 36(2):659-68. PMC: 4933553. DOI: 10.3892/or.2016.4858. View

4.
Koury M, Haase V . Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015; 11(7):394-410. PMC: 4497972. DOI: 10.1038/nrneph.2015.82. View

5.
Jiang X, Stockwell B, Conrad M . Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021; 22(4):266-282. PMC: 8142022. DOI: 10.1038/s41580-020-00324-8. View